These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 10832118)

  • 1. [The treatment and outlook of atherosclerosis today].
    Faggiotto A; Paoletti R
    Ital Heart J Suppl; 2000 Jan; 1(1):30-7. PubMed ID: 10832118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Dyslipidemias and cardiovascular diseases: towards a new perspective].
    Darioli R; Depairon M; Perdrix J; Mooser V
    Rev Med Suisse Romande; 2002 Oct; 122(10):489-93. PubMed ID: 12494781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From vulnerable plaque to vulnerable patient--Part III: Executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report.
    Naghavi M; Falk E; Hecht HS; Jamieson MJ; Kaul S; Berman D; Fayad Z; Budoff MJ; Rumberger J; Naqvi TZ; Shaw LJ; Faergeman O; Cohn J; Bahr R; Koenig W; Demirovic J; Arking D; Herrera VL; Badimon J; Goldstein JA; Rudy Y; Airaksinen J; Schwartz RS; Riley WA; Mendes RA; Douglas P; Shah PK;
    Am J Cardiol; 2006 Jul; 98(2A):2H-15H. PubMed ID: 16843744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipids for psychiatrists - an overview.
    Young IS
    J Psychopharmacol; 2005 Nov; 19(6 Suppl):66-75. PubMed ID: 16280339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pleiotropic effects of statins].
    Westerweel PE; Verhaar MC; Rabelink TJ
    Ned Tijdschr Geneeskd; 2004 Jul; 148(29):1431-5. PubMed ID: 15326645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease.
    Staels B; Maes M; Zambon A
    Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):542-53. PubMed ID: 18628776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noninvasive imaging of atherosclerotic vessels by MRI for clinical assessment of the effectiveness of therapy.
    Corti R
    Pharmacol Ther; 2006 Apr; 110(1):57-70. PubMed ID: 16445985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Atherosclerosis and simvastatin: new questions for the new millennium].
    Tubaro M; Guido V; Sciarra L; Mustilli M; Carbone MA; D'Errico F
    Ann Ital Med Int; 2000; 15(1):108-14. PubMed ID: 10842900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.
    Sharma R; Mahajan M; Singh B; Bal BS; Kant R
    J Indian Med Assoc; 2006 Sep; 104(9):492-4, 496, 498. PubMed ID: 17388006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.
    Jones PH
    Am J Cardiol; 2008 Dec; 102(12A):41L-47L. PubMed ID: 19084089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient.
    Ong HT
    QJM; 2005 Aug; 98(8):599-614. PubMed ID: 16006501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Atherosclerosis and arteriosclerosis of the small vessels in chronic renal insufficiency and after transplantation: lipid factors].
    Boizel R
    Nephrologie; 2000; 21(7):329-32. PubMed ID: 11200602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenomics and cardiovascular drugs: need for integrated biological system with phenotypes and proteomic markers.
    Siest G; Marteau JB; Maumus S; Berrahmoune H; Jeannesson E; Samara A; Batt AM; Visvikis-Siest S
    Eur J Pharmacol; 2005 Dec; 527(1-3):1-22. PubMed ID: 16316654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Epidemiology and prevention of cardiovascular diseases].
    Jánosi A
    Orv Hetil; 2005 Apr; 146(15):683-8. PubMed ID: 15895792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factor management: antiatherogenic therapies.
    Gielen S; Sandri M; Schuler G; Teupser D
    Eur J Cardiovasc Prev Rehabil; 2009 Aug; 16 Suppl 2():S29-36. PubMed ID: 19675434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polypharmacotherapy for primary prevention of cardiovascular disease.
    Xavier D; Devereaux PJ; Goyal A; Pais P; Yusuf S
    Indian Heart J; 2008; 60(2 Suppl B):B29-33. PubMed ID: 19359761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inflammation, the metabolic syndrome and cardiovascular risk.
    Tracy RP
    Int J Clin Pract Suppl; 2003 Mar; (134):10-7. PubMed ID: 12793593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plaque biology: interesting science or pharmacological treasure trove?
    Loftus I; Thompson M
    Eur J Vasc Endovasc Surg; 2008 Nov; 36(5):507-16. PubMed ID: 18625571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment.
    Libby P; Ridker PM
    Am J Med; 2004 Mar; 116 Suppl 6A():9S-16S. PubMed ID: 15050187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.